Sitagliptin: A novel agent for the management of type 2 diabetes mellitus

American Journal of Health-System Pharmacy

Volumn 65, Issue 6, 2008, Pages 521-531

  Pham, David Q ^a,b   Nogid, Anna ^c,d   Plakogiannis, Roda ^c,e  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b Fountain Valley Regional Hospital and Medical Center   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

^d BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^e Montefiore Medical Group Bronx East   (United States)

Author keywords

Antidiabetic agents; Combined therapy; Diabetes mellitus; Dosage; Drug interactions; Mechanism of action; Metformin; Pharmacokinetics; Sitagliptin; Thiazolidinediones; Toxicity

Indexed keywords

CYCLOSPORIN; DIGOXIN; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; 2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER FAILURE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; DRUG COMBINATION; DRUG INTERACTION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

DIABETES MELLITUS, TYPE 2; DIGOXIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 41049103817     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070248     Document Type: Review

References (42)

1. American Diabetes Association. Position statement: diagnosis and classification of diabetes mellitus. Diabetes Care. 2007; 30:S42-7.
2. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006; 29:1963-72.
3. McKennon SA, Campbell RK. The physiology of incretin hormones and the basis for DPP-4 inhibitors. Diabetes Educ. 2007; 33:55-66.
4. Lim GE, Brubaker PL. Glucagon-like peptide 1 secretion by the L-cell. The view from within. Diabetes. 2006; 55:S70-7.
5. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3:153-65.
6. Li Y, Hansotia T, Yusta B et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003; 278:471-8.
7. Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003; 144:5149-58.
8. Burcelin R, Da Costa A, Drucker D et al. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes. 2001; 50:1720-8.
9. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001; 86:3717-23.
10. Vilsboll T, Agerso H, Krarup T et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003; 88:220-4.
11. Mannucci E, Ognibene A, Cremasco F et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med. 2000; 17:713-9.
12. Rask E, Olsson T, Söderberg S et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care. 2001; 24:1640-5.
13. Theodorakis MJ, Carlson O, Muller DC et al. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care. 2004; 27:1692-8.
14. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept. 1999; 85:9-24.
15. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995; 80:952-7.
16. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005; 78:675-88.
17. Bergman AJ, Stevens C, Zhou YY et al. Pharmacokinetics and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo controlled study in healthy male volunteers. Clin Ther. 2006; 28:55-72.
18. Nauck MA, Kleine N, Orskov C et al. Normalization of fasting hyperglycaemia by exogenous glucagin-like peptide 1 (7-36 amide) in type 2 (non insulin-dependent) diabetic patients. Diabetologia. 1993; 36:741-4.
19. Deacon CF, Ahren B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs. 2004; 13:1091-102.
20. Holst JJ, Deacon CF. Glucagon like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol. 2004; 4:589-96.
21. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 91:4612-9.
22. 14C] sitagliptin in humans. Drug Metab Dispos. 2007; 35:533-8.
23. Chu XY, Bleasby K, Yabut J et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4Cl, and multidrug resistance p-glycoprotein. J Pharmacol Exp Ther. 2007; 321:673-83.
24. Bergman A, Ebel D, Liu F et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos. 2007; 28:315-22.
25. Herman GA, Bergman A, Liu F et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006; 46:876-86.
26. Bergman AJ, Cote J, Yi B. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007; 30:1862-4.
27. Stevens C, Bergman AJ, Liu Q et al. Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor. Clin Pharmacol Ther. 2006; 79:49. Abstract.
28. Aschner P, Kipnes MS, Lunceford JK et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29:2632-7.
29. Scott R, Wu M, Sanchez M et al. Efficacy and tolerability of the depeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007; 61:171-80.
30. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49:2564-71.
31. Brazg R, Xu L, Dalla Man C et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007; 9:186-93.
32. Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29:2638-43.
33. Nauck MA, Meininger G, Sheng D et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, noninferiority trial. Diabetes Obes Metab. 2007; 9:194-205.
34. Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28:1556-68.
35. Januvia (sitagliptin) package insert. Whitehouse Station, NJ: Merck and Co.; 2007.
36. Herman GA, Bergman A, Yi B et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006; 22:1939-47.
37. Mistry GC, Bergman AJ, Liu WL et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol. 2007; 47:159-64.
38. Krishna R, Bergman A, Larson P et al. Effect of a single cyclosporine dose on single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol. 2007; 47:165-74.
39. Miller JL, Migoya E, Talaty JE. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects. Clin Pharmacol Ther. 2006; 79:24. Abstract.
40. Wright D, Maes A, Yi B et al. Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin. Clin Pharmacol Ther. 2006; 79:76. Abstract.
41. Bergman AJ, Cote J, Maes A et al. Sitagliptin (MK-0431), a selective dipeptidyl peptidase-IV (DPP-IV) inhibitor, does not affect the pharmacokinetics of simvastatin in humans. Clin Pharmacol Ther. 2006; 79:48. Abstract.
42. Murray L, ed. Red book: pharmacy's fundamental reference, December 2006 update. Montvale, NJ: Thomson PDR; 2006.